MLL-Rearranged Acute Lymphoblastic Leukemias Activate BCL-2 through H3K79 Methylation and Are Sensitive to the BCL-2-Specific Antagonist ABT-199

Benito, Juliana M. ; Godfrey, Laura ; Kojima, Kensuke ; Hogdal, Leah ; Wunderlich, Mark ; Geng, Huimin ; Marzo, Isabel (Universidad de Zaragoza) ; Harutyunyan, Karine G. ; Golfman, Leonard ; North, Phillip ; Kerry, Jon ; Ballabio, Erica ; Chonghaile, Triona Ní ; Gonzalo, Oscar ; Qiu, Yihua ; Jeremias, Irmela ; Debose, LaKiesha ; O\u2019Brien, Eric ; Ma, Helen ; Zhou, Ping ; Jacamo, Rodrigo ; Park, Eugene ; Coombes, Kevin R. ; Zhang, Nianxiang ; Thomas, Deborah A. ; O\u2019Brien, Susan ; Kantarjian, Hagop M. ; Leverson, Joel D. ; Kornblau, Steven M. ; Andreeff, Michael ; Müschen, Markus ; Zweidler-McKay, Patrick A. ; Mulloy, James C. ; Letai, Anthony ; Milne, Thomas A. ; Konopleva, Marina

Resumen: Targeted therapies designed to exploit specific molecular pathways in aggressive cancers are an exciting area of current research. Mixed Lineage Leukemia (MLL) mutations such as the t(4;11) translocation cause aggressive leukemias that are refractory to conventional treatment. The t(4;11) translocation produces an MLL/AF4 fusion protein that activates key target genes through both epigenetic and transcriptional elongation mechanisms. In this study, we show that t(4;11) patient cells express high levels of BCL-2 and are highly sensitive to treatment with the BCL-2-specific BH3 mimetic ABT-199. We demonstrate that MLL/AF4 specifically upregulates the BCL-2 gene but not other BCL-2 family members via DOT1L-mediated H3K79me2/3. We use this information to show that a t(4;11) cell line is sensitive to a combination of ABT-199 and DOT1L inhibitors. In addition, ABT-199 synergizes with standard induction-type therapy in a xenotransplant model, advocating for the introduction of ABT-199 into therapeutic regimens for MLL-rearranged leukemias. Therapies designed to exploit specific molecular pathways in aggressive cancers are an exciting area of research. Mutations in the MLL gene cause aggressive incurable leukemias. Benito et al. show that MLL leukemias are highly sensitive to BCL-2 inhibitors, especially when combined with drugs that target mutant MLL complex activity.

Idioma: Inglés

DOI: 10.1016/j.celrep.2015.12.003

Año: 2015

Publicado en: Cell Reports 13, 12 (2015), 2715-2727
ISSN: 2211-1247

Factor impacto JCR: 7.87 (2015)

Categ. JCR: CELL BIOLOGY rank: 26 / 187 = 0.139 (2015) - Q1 - T1

Factor impacto SCIMAGO: 8.545 - Biochemistry, Genetics and Molecular Biology (miscellaneous) (Q1)

Tipo y forma: Article (Published version)

Área (Departamento): Área Biología Celular (Dpto. Bioq.Biolog.Mol. Celular)